Pharmaceutical

Business & Market Trends
Navigating US Trade Tariffs and International Policy Shifts in Life Sciences
Byvivek@webspero.com October 10, 2026September 21, 2026
For decades, pharmaceutical, biotechnology, and medical-device companies built global operations around specialization, scale, and relatively frictionless international trade. Active pharmaceutical ingredients (APIs), key starting materials (KSMs), laboratory inputs, and manufacturing services could be sourced from countries with established capabilities and competitive costs, while contract manufacturers supported production across multiple regions. That model is now being…
Read More Navigating US Trade Tariffs and International Policy Shifts in Life Sciences
Business & Market Trends
Mergers and Acquisitions (M&A) Outlook in the Global Pharma Sector
Byvivek@webspero.com October 9, 2026September 21, 2026
Pharmaceutical M&A is entering another important phase as large drugmakers confront a combination of expiring exclusivity, concentrated product revenues and the need to replenish late-stage pipelines. IQVIA estimates that more than $230 billion in biopharma revenue could face loss-of-exclusivity exposure by 2030, with additional exposure expected in the early 2030s. At the same time, large…
Read More Mergers and Acquisitions (M&A) Outlook in the Global Pharma Sector
Business & Market Trends
Venture Capital Funding Trends in Biotech & MedTech Startups
Byvivek@webspero.com October 8, 2026September 21, 2026
The era of enormous, oversubscribed biotech rounds based largely on promising preclinical science has given way to a more demanding funding environment. The latest biotech venture capital trends show investors placing greater weight on clinical evidence, capital efficiency, regulatory execution and credible routes to liquidity. In the first half of 2026, biopharma venture funding reached…
Read More Venture Capital Funding Trends in Biotech & MedTech Startups
Clinical Trials & Research
Patient Recruitment Strategies for Rare Disease Clinical Trials
Byvivek@webspero.com October 2, 2026September 21, 2026
Rare disease clinical trials face a recruitment problem that is fundamentally different from trials involving common conditions. The patients researchers need may be scattered across countries, treated by a small number of specialists, or still searching for a definitive diagnosis after years of inconclusive testing. This diagnostic odyssey can delay identification of eligible participants and…
Read More Patient Recruitment Strategies for Rare Disease Clinical Trials
Medical Science & Healthcare
Innovations in Neurodegenerative Disease Biomarker Quantitation
Byvivek@webspero.com September 27, 2026September 21, 2026
Neurodegenerative diseases have traditionally been diagnosed through a combination of clinical symptoms, cognitive or motor assessments, cerebrospinal fluid (CSF) analysis, and increasingly sophisticated brain imaging. Each approach has value, but each also has limitations. Lumbar puncture is invasive, PET imaging is expensive and not widely accessible, while clinical assessments can identify disease only after substantial…
Read More Innovations in Neurodegenerative Disease Biomarker Quantitation
Pharmaceutical News & Research
CAR-T Cell Therapy Expansion into Autoimmune Diseases
Byvivek@webspero.com September 26, 2026September 18, 2026
For decades, treatment of severe autoimmune disease has largely followed a suppression-and-maintenance model. Corticosteroids, conventional immunosuppressants and biologic therapies can control inflammation and prevent organ damage, but many patients remain dependent on long-term treatment and may relapse when therapy is withdrawn. The possibility of eliminating the immune cells that sustain disease has therefore attracted intense…
Read More CAR-T Cell Therapy Expansion into Autoimmune Diseases
Pharmaceutical News & Research
The Shift to Omnichannel Orchestration in Commercial Pharma Strategies
Byvivek@webspero.com September 25, 2026September 18, 2026
Pharmaceutical commercial engagement has traditionally operated through separate channels: field representatives made calls, marketing teams sent emails, digital teams ran campaigns, and brands hosted webinars or events. Each activity could be effective on its own, but the overall experience was often fragmented. For time-constrained healthcare professionals (HCPs), repeated or poorly timed messages can create noise…
Read More The Shift to Omnichannel Orchestration in Commercial Pharma Strategies
Pharmaceutical News & Research
Combating PBM Rebate Structures: What New Healthcare Bills Mean for Pharma
Byvivek@webspero.com September 24, 2026September 18, 2026
Pharmacy Benefit Managers (PBMs) have become central intermediaries in the U.S. prescription-drug supply chain. They negotiate with pharmaceutical manufacturers, build formularies, manage pharmacy networks, and determine how rebates and other price concessions flow between manufacturers, health plans, pharmacies, and patients. That position has also made PBM compensation and rebate structures a growing focus of policymakers…
Read More Combating PBM Rebate Structures: What New Healthcare Bills Mean for Pharma